Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.
Press releases published on July 21, 2025
Creative Diagnostics Launches HIV Infection Rhesus Monkey Models to Accelerate AIDS Research and Treatment Development
EIN Presswire
·
July 21, 2025
Creative Diagnostics announces highly specialized HIV Infection Rhesus Monkey Models to accelerate HIV/AIDS research. NEW YORK, NY, UNITED STATES, July 21, 2025 /EINPresswire.com/ -- As an expert in providing solutions to assist virology and …
Never Give Up Day — The Celebration the World Was Waiting For
EIN Presswire
·
July 21, 2025
Once an idea, now a global movement, Never Give Up Day is quickly becoming the emotional anchor the modern world embraces. NEW YORK, NY, UNITED STATES, July 21, 2025 /EINPresswire.com/ -- Celebrated each year on August 18, Never Give Up Day has emerged …
Creative Diagnostics Announces New Antibody Pairs for Enhanced Human Metapneumovirus (hMPV) Detection
EIN Presswire
·
July 21, 2025
Creative Diagnostics launches high-performance antibody pairs and antigens for the detection of hMPV. NEW YORK, NY, UNITED STATES, July 21, 2025 /EINPresswire.com/ -- Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and …
Pharmacolog USA, Inc. Acquires the Remaining Assets of Pharmacolog AB From Perpetua Medical
EIN Presswire
·
July 21, 2025
The Acquisition includes the WasteLog and Pharmacolog Dashboard Product line and the rights to the DrugLog product outside the Oncology market NEW YORK, NY, UNITED STATES, July 21, 2025 /EINPresswire.com/ -- The acquisition of assets, including WasteLog …
56 Executive Search Launches with a Focus on Elite, Human-Centered Executive Recruitment
EIN Presswire
·
July 21, 2025
Boutique executive search firm launches with a mission to deliver trusted, high-touch VP, Director, and C-suite placements across industries. SARATOGA SPRINGS, NY, UNITED STATES, July 21, 2025 /EINPresswire.com/ -- 56 Executive Search, a boutique …
Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease
GlobeNewswire
·
July 21, 2025
Longeveron has licensed issued US Patent 12,168,028 B2, entitled “Methods for obtaining cardiomyogenic precursor cells” from the University of Miami New patent protects a method to derive GHRH-Receptor+ cardiomyogenic cells from pluripotent stem cells ( …
Sharecare introduces Condition Masterclass to support patient education and health literacy for chronic disease management
GlobeNewswire
·
July 21, 2025
ATLANTA, July 21, 2025 (GLOBE NEWSWIRE) -- Sharecare, the health tech company that helps to improve care quality, drive better outcomes, and lower costs across the healthcare ecosystem, today announced a new patient education destination that empowers …
Spirair Receives FDA Clearance for TurbAlign, a New Bioabsorbable Implant That Helps Keep Nasal Passages Open After Sinus Surgery
GlobeNewswire
·
July 21, 2025
SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Spirair, Inc., an early-stage medical device company developing minimally invasive solutions to help otolaryngologists (ENTs) improve patient care, today announced that the U.S. Food and Drug …
VitalHub Announces Q2 2025 Conference Call Date
GlobeNewswire
·
July 21, 2025
TORONTO, July 21, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today that it will release financial results for its second quarter 2025 ended June 30, 2025 after market close on August 7, 2025. The …
Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq
GlobeNewswire
·
July 21, 2025
SAN DIEGO, July 21, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today …
Senti Bio’s Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum
GlobeNewswire
·
July 21, 2025
SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene …
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
GlobeNewswire
·
July 21, 2025
- New board members bring decades of experience in company building, corporate strategy, commercialization, and business development CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company …
Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025
GlobeNewswire
·
July 21, 2025
Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025 Gdańsk, Poland - July 21, 2025 - Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in the development of innovative technology for cancer …
UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
GlobeNewswire
·
July 21, 2025
Findings published in the journal of Clinical Genitourinary Cancer show patients remained event-free for a median of two years after achieving complete response with ZUSDURI (mitomycin) intravesical solution. Among the 17 patients who achieved complete …
Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar
GlobeNewswire
·
July 21, 2025
A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourth quarter of 2025 …
NKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative Diseases
GlobeNewswire
·
July 21, 2025
Troculeucel, a cryopreserved, autologous enhanced natural killer cell therapy, has demonstrated preliminary clinical benefit without any drug-related adverse events in two Phase I clinical trials in Alzheimer’s Disease. Company receives expanded access …
Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025
GlobeNewswire
·
July 21, 2025
WALTHAM, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …
Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025
GlobeNewswire
·
July 21, 2025
WATERTOWN, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious …
ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026
GlobeNewswire
·
July 21, 2025
Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a …
Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110
GlobeNewswire
·
July 21, 2025
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, …